Polymyositis and dermatomyositis laboratory findings: Difference between revisions

Jump to navigation Jump to search
Line 40: Line 40:
* Mechanic’s hands
* Mechanic’s hands
* Arthritis
* Arthritis
|Antisynthetase syndrome
|
* Antisynthetase syndrome
* Flare up in spring
* Epstein-Barr virus (EBV), adenovirus, and influenza infection
|
|
|
|
Line 54: Line 57:
|
|
|
|
* Flare up in fall
|
|
|
|
Line 60: Line 64:
|
|
|
|
* Epstein-Barr virus (EBV), adenovirus, and influenza infection
|
|
|
|
Line 66: Line 71:
|
|
|
|
* Cancer-associated myositis
* Juvenile dermatomyositis
|
|
|
|
Line 72: Line 79:
|
|
|
|
* Cancer-associated myositis
* Juvenile dermatomyositis
|
|
|
|
Line 78: Line 87:
|
|
|
|
* Cancer-associated myositis
|
|
|
|
Line 83: Line 93:
|Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)
|Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)
|immune-mediated necrotizing myopathies
|immune-mediated necrotizing myopathies
|statin-associated necrotizing autoimmune myopathy (SANAM)
|
* Statin-associated necrotizing autoimmune myopathy (SANAM)
|6%
|6%
|
|

Revision as of 16:04, 5 April 2018

Polymyositis and dermatomyositis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polymyositis and dermatomyositis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polymyositis and dermatomyositis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polymyositis and dermatomyositis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polymyositis and dermatomyositis laboratory findings

CDC on Polymyositis and dermatomyositis laboratory findings

Polymyositis and dermatomyositis laboratory findings in the news

Blogs on Polymyositis and dermatomyositis laboratory findings

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Polymyositis and dermatomyositis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].

OR

Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

OR

[Test] is usually normal for patients with [disease name].

OR

Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

OR

There are no diagnostic laboratory findings associated with [disease name].

Laboratory Findings

  • Laboratory findings consistent with the diagnosis of polymyositis and dermatomyositis include:[1]

Myositis-specific autoantibodies

Autoantibody Effect Association Percentage
Histidyl-tRNA synthetase (anti-Jo-1)
  • Myositis
  • Interstitial lung disease
  • Mechanic’s hands
  • Arthritis
  • Antisynthetase syndrome
  • Flare up in spring
  • Epstein-Barr virus (EBV), adenovirus, and influenza infection
Chromodomain helicase DNA binding protein 4 (Mi-2)
  • Severe dermatomyositis rash without significant lung involvement 
Signal recognition particle (anti-SRP)
  • Flare up in fall
Alanyl-tRNA synthetase (PL-12)
  • Epstein-Barr virus (EBV), adenovirus, and influenza infection
Transcriptional intermediary factor 1-gamma (TIF-1γ)
  • Cancer-associated myositis
  • Juvenile dermatomyositis
Nuclear matrix protein (NXP-2)
  • Cancer-associated myositis
  • Juvenile dermatomyositis
Anti-small ubiquitin-like modifier activating enzyme (anti-SAE)
  • Cancer-associated myositis
Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) immune-mediated necrotizing myopathies
  • Statin-associated necrotizing autoimmune myopathy (SANAM)
6%

References

  1. Adler BL, Christopher-Stine L (February 2018). "Triggers of inflammatory myopathy: insights into pathogenesis". Discov Med. 25 (136): 75–83. PMID 29579414.